Idan Elmelech
COO & Principal Financial Ofcr · BridgeBio Oncology Therapeutics, Inc.
Individual
- 2026
- Oct 5, 2026
- 3
Filings (90d)
Other insiders active in the same sector
No other insider has filed at Idan Elmelech's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- AI DMI LLC - $59.87M in IRON purchases and sales in the last 12 months
- RA CAPITAL MANAGEMENT, L.P. - $59.04M in SGP purchases and sales in the last 12 months
- Mark A. Goldsmith - $56.99M in RVMD purchases and sales in the last 12 months
- Peter A. Thompson - $55.67M in SION purchases and sales in the last 12 months
- ORBIMED ADVISORS LLC - $55.67M in SION purchases and sales in the last 12 months
- John E. Kao - $54.16M in ALHC purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Idan Elmelech?
Idan Elmelech is a corporate insider, tracked as COO & Principal Financial Ofcr of BridgeBio Oncology Therapeutics, Inc. (BBOT). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Idan Elmelech submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
